American Heart Journal
Volume 152, Issue 1 , Pages 1-3 , July 2006

Biomarker screening for cardiac dysfunction: The more the merrier?

  • W.H. Wilson Tang, MD

      Affiliations

    • Corresponding Author InformationReprint requests: W.H. Wilson Tang, MD, Department of Cardiovascular Medicine, Cleveland Clinic Foundation, 9500 Euclid Avenue, F25, Cleveland, OH 44195.

Received 31 October 2005 ,Accepted 19 January 2005.

References 

  1. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005;112:1825–1852
  2. Baker DW, Bahler RC, Finkelhor RS, et al. Screening for left ventricular systolic dysfunction among patients with risk factors for heart failure. Am Heart J. 2003;146:736–740
  3. Senior R, Galasko G, McMurray JV, et al. Screening for left ventricular dysfunction in the community: role of hand held echocardiography and brain natriuretic peptides. Heart. 2003;89(Suppl 3):iii24–iii28
  4. Vourvouri EC, Schinkel AF, Roelandt JR, et al. Screening for left ventricular dysfunction using a hand-carried cardiac ultrasound device. Eur J Heart Fail. 2003;5:767–774
  5. Davies M, Hobbs F, Davis R, et al. Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study. Lancet. 2001;358:439–444
  6. Bibbins-Domingo K, Ansari M, Schiller NB, et al. Is B-type natriuretic peptide a useful screening test for systolic or diastolic dysfunction in patients with coronary disease? Data from the Heart and Soul Study. Am J Med. 2004;116:509–516
  7. Galasko GI, Lahiri A, Barnes SC, et al. What is the normal range for N-terminal pro–brain natriuretic peptide? How well does this normal range screen for cardiovascular disease?. Eur Heart J. 2005;26:2269–2276
  8. Hedberg P, Lonnberg I, Jonason T, et al. Electrocardiogram and B-type natriuretic peptide as screening tools for left ventricular systolic dysfunction in a population-based sample of 75-year-old men and women. Am Heart J. 2004;148:524–529
  9. Maisel AS, Koon J, Krishnaswamy P, et al. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J. 2001;141:367–374
  10. Vasan RS, Benjamin EJ, Larson MG, et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham Heart Study. JAMA. 2002;288:1252–1259
  11. Redfield MM, Rodeheffer RJ, Jacobsen SJ, et al. Plasma brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dysfunction: a community-based study. Circulation. 2004;109:3176–3181
  12. Ng LL, Pathik B, Loke IW, et al. Myeloperoxidase and C-reactive protein augment the specificity of B-type natriuretic peptide in community screening for systolic heart failure. Am Heart J. 2005;[in press]
  13. Heidenreich PA, Gubens MA, Fonarow GC, et al. Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. J Am Coll Cardiol. 2004;43:1019–1026
  14. Mann DL, Bristow MR. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation. 2005;111:2837–2849
  15. Askari AT, Brennan ML, Zhou X, et al. Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction. J Exp Med. 2003;197:615–624
  16. Vasilyev M, Williams T, Brennan ML, et al. Myeloperoxidase-generated oxidants modulate left ventricular remodeling but not infarct size following myocardial infarction. Circulation. 2005;112:2812–2820
  17. Gottdiener JS, Arnold AM, Aurigemma GP, et al. Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol. 2000;35:1628–1637
  18. Aviles RJ, Brennan ML, Katz R, et al. Myeloperoxidase modulates risk for developing congestive heart failure. (abstract) Circulation. 2005;112(Suppl):II–724
  19. Tang WH, Brennan ML, Philip K, et al. Elevated plasma myeloperoxidase levels in patients with chronic systolic heart failure. (abstract) Circulation. 2005;112(Suppl):II–725
  20. Lamblin N, Mouquet F, Hennache B, et al. High-sensitivity C-reactive protein: potential adjunct for risk stratification in patients with stable congestive heart failure. Eur Heart J. 2005;26:2245–2250
  21. Anand IS, Latini R, Florea VG, et al. C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation. 2005;112:1428–1434
  22. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med. 2004;350:655–663
  23. Tang WH, Philip K, Hazen SL, et al. Comparative sensitivities between different plasma B-type natriuretic peptide assays in patients with minimally symptomatic heart failure. Clin Cornerstone. 2005;7(Suppl 1):S18–S24

 Dr Tang previously received a one-time honorarium from Abbott Diagnostics Inc and from Roche Diagnostics Inc.

PII: S0002-8703(06)00049-4

doi: 10.1016/j.ahj.2006.01.002

American Heart Journal
Volume 152, Issue 1 , Pages 1-3 , July 2006

Article Tools